| 曹建中,丁亚亭,马剑波,冯建军,钱坤艳.CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的临床研究[J].,2020,(19):3736-3739 |
| CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的临床研究 |
| Clinical Study of CAP Regimen Combined with Aidi Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
| 投稿时间：2020-01-28 修订日期：2020-02-24 |
| DOI：10.13241/j.cnki.pmb.2020.19.029 |
| 中文关键词: 艾迪注射液 CAP方案 非小细胞肺癌 免疫功能 生活质量 |
| 英文关键词: Aidi injection CAP regimen Non-small cell lung cancer Immune function Quality of life |
| 基金项目:江苏省重点研发计划项目（BE2019692）；南通市民生科技重点项目（MS32018010） |
|
| 摘要点击次数: 845 |
| 全文下载次数: 455 |
| 中文摘要: |
| 摘要 目的：研究CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的效果。方法：选择2016年1月～2019年1月我院的81例晚期非小细胞肺癌患者，随机分为两组。对照组的41例晚期非小细胞肺癌患者采用CAP方案，即快速静脉滴注吡柔比星50 mg/m2和环磷酰胺600 mg/m2，d1，顺铂80 mg/m2，d2-d4，1 个周期为28 d，共治疗2个周期。观察组的40例晚期非小细胞肺癌患者联合静脉滴注艾迪注射液，每次50 mL，每天1次，1个疗程为3 w，共治疗3个疗程。比较两组的免疫功能、生活质量和不良反应情况。结果：观察组的有效率明显高于对照组(P<0.05）；观察组治疗后的CD4+、CD3+及CD4+/CD8+明显升高(P<0.05），且明显高于对照组(P<0.05）；观察组的生活质量提高17例，稳定10例，降低6例，观察组的生活质量改善率为82.50%（33/40），明显高于对照组的53.66%（22/41）(P<0.05）；观察组的消化道反应发生率明显低于对照组(P<0.05），两组的过敏反应、神经毒性和脱发发生率无明显差异(P>0.05）。结论：艾迪注射液联合CAP方案可以提高晚期非小细胞肺癌的化疗疗效以及生活质量，改善免疫功能，减轻化疗所致的不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of CAP regimen combined with Aidi injection in the treatment of advanced non-small cell lung cancer. Methods: Selected 81 cases of patients with advanced non-small cell lung cancer who were treated in our hospital from January 2016 to January 2019, divided into two groups randomly. In the control group, 41 patients with advanced non-small cell lung cancer were treated with CAP regimen, rapid intravenous drip of pirarubicin 50 mg/m2 and cyclophosphamide 600 mg/m2, d1, cisplatin 80 mg/m2, d2-d4, a cycle of 28 days, a total of 2 cycles. The observation group of 40 patients with advanced non-small cell lung cancer combined with intravenous drip of Aidi injection, 50 mL each time, once a day, a course of 3 weeks, a total of three courses of treatment. The immune function, quality of life and adverse reactions were compared between the two groups. Results: The effective rate of the observation group was significantly higher than control group(P<0.05). After treatment, the levels of CD4+, CD3+, CD4+/CD8+ in the observation group were significantly higher than those in the control group(P<0.05）. The quality of life in the observation group was improved in 17 cases, stabilized in 10 cases and decreased in 6 cases. The improvement rate of the quality of life in the observation group was 82.50% (33/40), which was significantly higher than that in the control group (53.66% (22/41)(P<0.05). The incidence of digestive tract reaction in the observation group was significantly lower than that in the control group(P<0.05）. There was no significant difference in the incidence of allergic reaction, neurotoxicity and alopecia between the two groups(P>0.05). Conclusion: Aidi injection combined with CAP regimen can improve the efficacy and quality of life of patients with advanced non-small cell lung cancer, improve immune function and alleviate adverse reactions caused by chemotherapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
